Where Does the Evidence Lead Us for the Proper Use of Angiotensin II Inhibitors in the Management of Cardiovascular Disease?

Publisher： Karger

E-ISSN： 1421-9751|117|3|216-218

ISSN： 0008-6312

Source： Cardiology, Vol.117, Iss.3, 2010-12, pp. : 216-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

From Evidence to Rationale: Cardiovascular Protection by Angiotensin II Receptor Blockers Compared with Angiotensin-Converting Enzyme Inhibitors

By  

Cardiology, Vol. 117, Iss. 3, 2010-11 ,pp. : 163-173

Karger

Access to resources Recommend Favorite

Predicting the Risk of Cardiovascular Disease: Where Does Lipoprotein-Associated Phospholipase A2 Fit In?

By Khuseyinova Natalie   Koenig Wolfgang  

Molecular Diagnosis & Therapy, Vol. 11, Iss. 4, 2007-01 ,pp. : 203-217

Adis International

Access to resources Recommend Favorite

Angiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy

By Ribeiro Artur Beltrame  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 1-16

Informa Healthcare

Access to resources Recommend Favorite

Is there Evidence to Support the Use of Direct Factor Xa Inhibitors in Coronary Artery Disease?

By  

Reviews on Recent Clinical Trials, Vol. 6, Iss. 2, 2011-05 ,pp. : 147-157

Bentham Science Publishers

Access to resources Recommend Favorite

The Management of Cardiovascular Disease in the Elderly

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 30, Iss. S11, 1982-11 ,pp. : S20-S29

John Wiley & Sons Inc

Access to resources Recommend Favorite